Talipexole
Modify Date: 2025-08-25 22:21:31
Talipexole structure
|
Common Name | Talipexole | ||
|---|---|---|---|---|
| CAS Number | 101626-70-4 | Molecular Weight | 209.31 | |
| Density | 1.167g/cm3 | Boiling Point | 364.6ºC at 760mmHg | |
| Molecular Formula | C10H15N3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 174.3ºC | |
Use of TalipexoleTalipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent.Target: Dopamine ReceptorB-HT920 is a selective alpha 2-adrenoceptor agonist. The effects of B-HT920 have been specified using the alpha-adrenergic antagonists yohimbine and prazosin and the dopamine antagonist haloperidol. Yohimbine could not antagonize any of the actions of B-HT920. Pretreatment with prazosin showed a decrease in the loss of body weight caused by B-HT920, while pretreatment with yohimbine showed that B-HT920 induced an increased loss in body weight. These data suggest that B-HT920 under certain conditions exerts dopamine-agonistic actions in stimulating locomotor activity and alpha 1-adrenergic actions in inducing salivation and enhanced loss of body weight [1]. Concomitant treatment with talipexole, an anti-parkinsonian drug, inhibited MPTP-induced autolysis and individual death in a concentration-dependent manner. Pramipexole showed a similar protective effect. In addition, post-treatment with talipexole at 1 hr after MPTP completely inhibited MPTP-induced individual death. Although MPTP treatment caused 30% of the planarians to undergo autolysis and individual death within 12 hr, post-treatment with talipexole even at 12 hr completely rescued the remaining 70% of the planarians from death. These results suggest that the MPTP-treated planarian may be useful as a novel parkinsonian model in which talipexole has a protective effect even in the case of post-treatment [2]. |
| Name | 6-prop-2-enyl-4,5,7,8-tetrahydro-[1,3]thiazolo[4,5-d]azepin-2-amine |
|---|---|
| Synonym | More Synonyms |
| Description | Talipexole (B-HT920) is a dopamine agonist that has been proposed as an antiparkinsonian agent.Target: Dopamine ReceptorB-HT920 is a selective alpha 2-adrenoceptor agonist. The effects of B-HT920 have been specified using the alpha-adrenergic antagonists yohimbine and prazosin and the dopamine antagonist haloperidol. Yohimbine could not antagonize any of the actions of B-HT920. Pretreatment with prazosin showed a decrease in the loss of body weight caused by B-HT920, while pretreatment with yohimbine showed that B-HT920 induced an increased loss in body weight. These data suggest that B-HT920 under certain conditions exerts dopamine-agonistic actions in stimulating locomotor activity and alpha 1-adrenergic actions in inducing salivation and enhanced loss of body weight [1]. Concomitant treatment with talipexole, an anti-parkinsonian drug, inhibited MPTP-induced autolysis and individual death in a concentration-dependent manner. Pramipexole showed a similar protective effect. In addition, post-treatment with talipexole at 1 hr after MPTP completely inhibited MPTP-induced individual death. Although MPTP treatment caused 30% of the planarians to undergo autolysis and individual death within 12 hr, post-treatment with talipexole even at 12 hr completely rescued the remaining 70% of the planarians from death. These results suggest that the MPTP-treated planarian may be useful as a novel parkinsonian model in which talipexole has a protective effect even in the case of post-treatment [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.167g/cm3 |
|---|---|
| Boiling Point | 364.6ºC at 760mmHg |
| Molecular Formula | C10H15N3S |
| Molecular Weight | 209.31 |
| Flash Point | 174.3ºC |
| PSA | 70.39000 |
| LogP | 3.43500 |
| Vapour Pressure | 1.66E-05mmHg at 25°C |
| Index of Refraction | 1.596 |
| InChIKey | DHSSDEDRBUKTQY-UHFFFAOYSA-N |
| SMILES | C=CCN1CCc2nc(N)sc2CC1 |
| Storage condition | 2-8℃ |
| Talipexolum [Latin] |
| Talipexol [Spanish] |
| Talipexole (INN) |
| Talipexole |
| B-HT 920 |